Sodium Valproate Latest
Below we have collated the latest information relating to Sodium Valproate
Nicola Swanborough unpicks the issues around valproate and explains why the risks and benefits of the medication must be properly discussed and evidenced in public, before new prescribing practices potentially put people with epilepsy at risk of seizures
The UK epilepsy organisations listed below are joining together in an urgent call for a decision by the Medicines and Healthcare products Regulatory Agency (MHRA) and Ministers to be paused immediately.
We have been advised by the medicines regulator – the MHRA – that there are to be some important changes made to the way that valproate is prescribed. This will affect both men and women under the age of 55 and girls of childbearing age.
Two new initiatives have been launched to help ensure that all women with epilepsy, of child-bearing age, are aware of the risks associated with the medication valproate, during pregnancy.
The House of Lords has discussed the need for a redress scheme for mothers and babies harmed by sodium valproate.
Sodium valproate is an epilepsy drug prescribed for all seizure types including absence, myoclonus and tonic clonic seizures. New regulations have been introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) around the way in which the drug, sodium valproate is prescribed to women and girls of childbearing age.
Most women with epilepsy do not have any change in their seizure frequency during pregnancy. However you might find that your seizures are better controlled during pregnancy, or that you have more seizures than is usual for you.
If you have just been diagnosed with epilepsy, you may have questions about medication and treatment.